Photodynamic Therapy - Basic Science Studies

光动力疗法 - 基础科学研究

• 批准号: 6817708
• 负责人: FRED W HETZEL
• 金额: $ 75.47万
• 依托单位: HEALTHONE ALLIANCE
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-01-01 至 2008-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6817708
• 关键词: brain neoplasms; clinical research; human subject; neoplasm /cancer photoradiation therapy; photosensitizing agents

DESCRIPTION (provided by applicant): This Program Project will continue to investigate Photodynamic Therapy (PDT) as applied to solid tumor therapy. The clinical applications will focus on malignant brain tumors and prostate cancer. The four projects will cover research topics ranging from basic molecular and cellular responses to PDT to the conduct of novel clinical trials employing PDT. The projects are supported by two cores that are integral to the overall success of the Program. The synergy of the Program will continue to depend upon the effective interactions between both the scientific and clinical projects and the investigators. Project 1 will investigate in preclinical models novel strategies for the improved treatment of brain tumors. This project will incorporate aim one from prior Project 4 examining and comparing the molecular effects of ALA-mediated metronomic PDT versus acute ALA-mediated PDT in brain tumor. Project 2 consists of both ongoing and new clinical trials for the treatment of brain tumors. Project 3 will investigate in canine and murine models the possible use of PDT for the treatment of prostate tumors employing a novel, second-generation sensitizer, Tookad. Project 5 (not renumbered) will focus on the development of new biophysical techniques for monitoring PDT in vivo and on translating already developed methods and devices into clinical applications. Core 1 will provide the necessary administrative support for the overall Program and Core 2 will provide technical support to all of the preclinical and clinical projects.

描述（由申请人提供）：本项目将继续研究光动力学疗法（PDT）应用于实体瘤治疗。临床应用将集中在恶性脑肿瘤和前列腺癌。这四个项目将涵盖从PDT的基本分子和细胞反应到使用PDT进行新的临床试验的研究课题。这些项目得到两个核心的支持，这两个核心是该方案取得全面成功的必要条件。该计划的协同作用将继续取决于科学和临床项目与研究人员之间的有效互动。项目1将在临床前模型中研究改善脑肿瘤治疗的新策略。本项目将结合之前项目4的目标之一，检查和比较ALA介导的节拍PDT与急性ALA介导的PDT在脑肿瘤中的分子效应。项目2包括正在进行的和新的临床试验， 脑肿瘤的治疗项目3将在犬和小鼠模型中研究采用新型第二代敏化剂Tookad进行PDT治疗前列腺肿瘤的可能性。项目5（未重新编号）将侧重于开发用于体内监测PDT的新生物物理技术，并将已开发的方法和设备转化为临床应用。核心1将为整个项目提供必要的行政支持，核心2将为所有临床前和临床项目提供技术支持。